- Home
- PLX vs CIGL Comparison
PLX vs CIGL Comparison
Compare PLX & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CIGL
- Stock Information
- Founded
- PLX 1993
- CIGL 1997
- Country
- PLX United States
- CIGL Singapore
- Employees
- PLX N/A
- CIGL N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CIGL Diversified Commercial Services
- Sector
- PLX Health Care
- CIGL Consumer Discretionary
- Exchange
- PLX Nasdaq
- CIGL Nasdaq
- Market Cap
- PLX 122.6M
- CIGL 145.9M
- IPO Year
- PLX 1998
- CIGL 2025
- Fundamental
- Price
- PLX $1.37
- CIGL $3.77
- Analyst Decision
- PLX Strong Buy
- CIGL
- Analyst Count
- PLX 1
- CIGL 0
- Target Price
- PLX $15.00
- CIGL N/A
- AVG Volume (30 Days)
- PLX 1.3M
- CIGL 721.0K
- Earning Date
- PLX 08-13-2025
- CIGL 01-01-0001
- Dividend Yield
- PLX N/A
- CIGL N/A
- EPS Growth
- PLX N/A
- CIGL N/A
- EPS
- PLX 0.05
- CIGL N/A
- Revenue
- PLX $59,764,000.00
- CIGL $10,490,668.00
- Revenue This Year
- PLX $65.02
- CIGL N/A
- Revenue Next Year
- PLX $57.34
- CIGL N/A
- P/E Ratio
- PLX $28.34
- CIGL N/A
- Revenue Growth
- PLX 0.18
- CIGL N/A
- 52 Week Low
- PLX $0.82
- CIGL $2.12
- 52 Week High
- PLX $3.10
- CIGL $31.06
- Technical
- Relative Strength Index (RSI)
- PLX 41.78
- CIGL N/A
- Support Level
- PLX $1.43
- CIGL N/A
- Resistance Level
- PLX $1.54
- CIGL N/A
- Average True Range (ATR)
- PLX 0.09
- CIGL 0.00
- MACD
- PLX 0.01
- CIGL 0.00
- Stochastic Oscillator
- PLX 5.77
- CIGL 0.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.